Advertisement
Screener

LENZ THERAPEUTICS, INC. (LENZ) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

LENZ THERAPEUTICS, INC. Operating Cash Flow

LENZ THERAPEUTICS, INC. (LENZ) reported Operating Cash Flow of -$72.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11

  • LENZ THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$38.71M.
  • LENZ THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$33.58M.
  • LENZ THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$33.02M.
  • LENZ THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$8.59M.
  • LENZ THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$69.17M.
  • LENZ THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$59.39M.
  • LENZ THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$60.38M.
  • LENZ THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$87.98M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$38.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
-$72.30M
10-Q · filed 2026-08-11
-$105.32M
derived: sum of 3 quarters · filed 2026-08-11
-$113.91M
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31-$33.58M
10-Q · filed 2026-05-11
-$66.61M
derived: sum of 2 quarters · filed 2026-05-11
-$75.19M
derived: sum of 3 quarters · filed 2026-05-11
-$86.70M
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31-$33.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$41.61M
derived: sum of 2 quarters · filed 2026-03-24
-$53.12M
derived: sum of 3 quarters · filed 2026-08-11
-$69.17M
10-K · filed 2026-03-24
2025-09-30-$8.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$20.10M
derived: sum of 2 quarters · filed 2026-08-11
-$36.15M
10-Q · filed 2025-11-05
-$45.22M
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30-$11.51M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
-$27.56M
10-Q · filed 2026-08-11
-$36.63M
derived: sum of 3 quarters · filed 2026-08-11
-$47.22M
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31-$16.05M
10-Q · filed 2026-05-11
-$25.13M
derived: sum of 2 quarters · filed 2026-05-11
-$35.71M
derived: sum of 3 quarters · filed 2026-05-11
-$51.50M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31-$9.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$19.66M
derived: sum of 2 quarters · filed 2026-03-24
-$35.45M
derived: sum of 3 quarters · filed 2026-03-24
-$59.39M
10-K · filed 2026-03-24
2024-09-30-$10.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$26.38M
derived: sum of 2 quarters · filed 2025-11-05
-$50.31M
10-Q · filed 2025-11-05
-$71.28M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30-$15.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30
-$39.73M
10-Q · filed 2025-07-30
-$60.70M
derived: sum of 3 quarters · filed 2025-07-30
-$73.79M
derived: sum of 4 quarters · filed 2025-07-30
2024-03-31-$23.94M
10-Q · filed 2025-05-07
-$44.91M
derived: sum of 2 quarters · filed 2025-05-07
-$57.99M
derived: sum of 3 quarters · filed 2025-05-07
-$71.52M
derived: sum of 4 quarters · filed 2025-05-07
2023-12-31-$20.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19
-$34.06M
derived: sum of 2 quarters · filed 2025-03-19
-$47.58M
derived: sum of 3 quarters · filed 2025-03-19
-$60.38M
10-K · filed 2025-03-19
-$90.01M
10-K · filed 2024-02-27
2023-09-30-$13.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
-$26.61M
derived: sum of 2 quarters · filed 2024-11-06
-$39.41M
10-Q · filed 2024-11-06
-$44.13M
10-Q · filed 2023-11-13
-$61.84M
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30-$13.52M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$26.32M
10-Q · filed 2024-08-14
-$34.73M
10-Q · filed 2023-08-14
-$48.75M
derived: sum of 3 quarters · filed 2024-08-14
-$70.97M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31-$12.80M
10-Q · filed 2024-05-08
-$21.07M
10-Q · filed 2023-05-11
-$35.23M
derived: sum of 2 quarters · filed 2024-05-08
-$57.44M
derived: sum of 3 quarters · filed 2024-05-08
-$79.54M
derived: sum of 4 quarters · filed 2024-05-08
2022-12-31-$22.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
-$44.65M
derived: sum of 2 quarters · filed 2024-02-27
-$66.74M
derived: sum of 3 quarters · filed 2024-02-27
-$87.98M
10-K · filed 2024-02-27
2022-09-30-$22.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$44.31M
derived: sum of 2 quarters · filed 2023-11-13
-$65.55M
10-Q · filed 2023-11-13
-$81.14M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$22.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$43.33M
10-Q · filed 2023-08-14
-$58.93M
derived: sum of 3 quarters · filed 2023-08-14
-$74.34M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$21.24M
10-Q · filed 2023-05-11
-$36.83M
derived: sum of 2 quarters · filed 2023-05-11
-$52.25M
derived: sum of 3 quarters · filed 2023-05-11
-$66.03M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$15.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20
-$31.01M
derived: sum of 2 quarters · filed 2023-03-20
-$44.79M
derived: sum of 3 quarters · filed 2023-03-20
-$52.85M
10-K · filed 2023-03-20
2021-09-30-$15.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$29.20M
derived: sum of 2 quarters · filed 2022-11-09
-$37.26M
10-Q · filed 2022-11-09
-$42.53M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30-$13.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$21.84M
10-Q · filed 2022-08-11
-$27.11M
derived: sum of 3 quarters · filed 2022-08-11
-$29.61M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$8.06M
10-Q · filed 2022-05-12
-$13.33M
derived: sum of 2 quarters · filed 2022-05-12
-$15.82M
derived: sum of 3 quarters · filed 2022-05-12
2020-12-31-$5.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21
-$7.76M
derived: sum of 2 quarters · filed 2022-03-21
-$8.72M
10-K · filed 2022-03-21
2020-09-30-$2.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$3.45M
10-Q · filed 2021-11-10
2020-06-30-$957.00K
10-Q · filed 2021-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48